Modality
Multispecific
MOA
KRASG12Di
Target
CD3
Pathway
Amyloid
MyelofibrosisDravetT2D
Development Pipeline
Preclinical
~Apr 2012
→ ~Jul 2013
Phase 1
~Oct 2013
→ ~Jan 2015
Phase 2
~Apr 2015
→ ~Jul 2016
Phase 3
~Oct 2016
→ ~Jan 2018
NDA/BLA
Apr 2018
→ Apr 2031
NDA/BLACurrent
NCT07586864
1,707 pts·Dravet
2018-04→2031-04·Terminated
1,707 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-045.0y awayPh3 Readout· Dravet
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2031-04-04 · 5.0y away
Dravet
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07586864 | NDA/BLA | Dravet | Terminated | 1707 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |